Journal Article

Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases

Jung, Minsun, Lee, Jinhee, Lee, Hajin, Park, Jongchan, Pereira, Sergio, Cho, Soo Ick, Kang, Mingu, Park, Jiyoung, Jung, Wonkyung, Shin, Sangwon, Lee, Taebum, Park, Gahee, Yoo, Donggeun, Park, Seonwook, Chung, Keunhyung, Song, Seung Geun, Song, Sanghoon, Song, Heon, Kim, So-Woon, Ali, Siraj M.

2024

Overview

Background Accurate classification of breast cancer molecular subtypes is crucial in determining treatment strategies and predicting clinical outcomes. This classification largely depends on the assessment of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) status. However, variability in interpretation among pathologists pose challenges to the accuracy of this classification. This study evaluates the role of artificial intelligence (AI) in enhancing the consistency of these evaluations. Methods AI-powered HER2 and ER/PR analyzers, consisting of cell and tissue models, were developed using 1,259 HER2, 744 ER, and 466 PR-stained immunohistochemistry (IHC) whole-slide images of breast cancer. External validation cohort comprising HER2, ER, and PR IHCs of 201 breast cancer cases were analyzed with these AI-powered analyzers. Three board-certified pathologists independently assessed these cases without AI annotation. Then, cases with differing interpretations between pathologists and the AI analyzer were revisited with AI assistance, focusing on evaluating the influence of AI assistance on the concordance among pathologists during the revised evaluation compared to the initial assessment. Results Reevaluation was required in 61 (30.3%), 42 (20.9%), and 80 (39.8%) of HER2, in 15 (7.5%), 17 (8.5%), and 11 (5.5%) of ER, and in 26 (12.9%), 24 (11.9%), and 28 (13.9%) of PR evaluations by the pathologists, respectively. Compared to initial interpretations, the assistance of AI led to a notable increase in the agreement among three pathologists on the status of HER2 (from 49.3 to 74.1%, p  < 0.001), ER (from 93.0 to 96.5%, p  = 0.096), and PR (from 84.6 to 91.5%, p  = 0.006). This improvement was especially evident in cases of HER2 2+ and 1+, where the concordance significantly increased from 46.2 to 68.4% and from 26.5 to 70.7%, respectively. Consequently, a refinement in the classification of breast cancer molecular subtypes (from 58.2 to 78.6%, p  < 0.001) was achieved with AI assistance. Conclusions This study underscores the significant role of AI analyzers in improving pathologists' concordance in the classification of breast cancer molecular subtypes.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Algorithms / Analytical instruments / Artificial Intelligence / Artificial intelligence (AI) / Artificial intelligence in breast imaging / Biomarkers, Tumor - metabolism / Biomedical and Life Sciences / Biomedicine / Breast cancer / Breast Neoplasms - diagnosis / Breast Neoplasms - metabolism / Cancer / Cancer Research / Cell culture / Concordance / Datasets / Digital pathology / Epidermal growth factor / ErbB-2 protein / Estrogen / Estrogen receptor (ER) / Estrogen receptors / Estrogens / Female / Human epidermal growth factor receptor 2 (HER2) / Humans / Immunohistochemistry / Monoclonal antibodies / Observer Variation / Oncology / Oncology, Experimental / Progesterone / Receptor, ErbB-2 - metabolism / Receptors, Estrogen - metabolism / Receptors, Progesterone - metabolism / Surgical Oncology